AmVac AG Granted a European Patent for ProstaVac

ZUG, Switzerland, June 18, 2010 - European patent EP 1272216B1 with the title "Vaccine consisting of
lactobacilli for the treatment of inflammation of the prostate and benign
prostatic hyperplasia" was granted by the European Patent Office on 9.6.2010.
AmVac AG, a biopharmaceutical company located in Zug, Switzerland, holds a
licence for the above patent.

Granting of the patent is a major success with regard to AmVac's vaccine
candidate "ProstaVac". AmVac AG acquired the licence for "ProstaVac" as an
immunotherapeutic agent for the treatment of prostatitis and BPH (benign
prostatic hyperplasia). These uses are protected in the above EP patent.

Prostatitis is a painful irritative condition of the prostate which is
caused by a non-specific inflammation. The pathogens track back up the
urethra and can spread in the prostatic ducts. The symptoms that occur range
from micturition disorders (problems passing water), urge and pain, to chills
and sexual dysfunction. The symptoms can severely impair the quality of life
and are often associated with long-term sexual dysfunction.

A variety of preparations are used to treat prostatitis. These include
antibiotics or so-called alpha-blockers for chronic prostatitis.

Benign prostate hyperplasia (BPH) is attributable to uncontrolled growth
of the prostate in which the prostate presses on the urethra. In the early
stages the symptoms are severe impairment of micturition with pain and weak
urine stream as well as urinary retention and, in some cases, incontinence.

In all cases the disorder sharply limits the quality of life due to the
urgent need to urinate, incontinence, and sexual dysfunction (impotence).
These disorders affect large parts of the male population: today, every
second 50- to 60-year-old man is affected by the condition. This figure rises
to about 90% in the 80-year-olds. Due to demographic developments and the
continuing increase in life expectancy, we must expect the number of patients
to increase further. It is currently estimated at about 12% a year. Although
the causes of the onset of BPH have not been fully clarified, a relationship
with infection is suspected.

The advanced stage is treated with medicines (plant-based preparations,
alpha-1-receptor blockers or 5-alpha-reductase inhibitors); thereafter,
surgery is required.

AmVac AG

AmVac AG is a biopharmaceutical company situated in Switzerland. The
company focuses on the vaccine market with its above-average growth figures.
There are two therapeutic vaccines in the pipeline, which are soon to be
launched in the fields of gynaecology and urology. Further innovative
vaccines and technologies are at the development stage.

Contact: Ariane Meynert, Head of PR/IR; Mail: meynert@amvac.ch Tel.:
+41-41-725-3234 Cell: +41-79-79-334-19

Contact: Ariane Meynert, Head of PR/IR; Mail: meynert at amvac.ch Tel.: +41-41-725-3234 Cell: +41-79-79-334-19